Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.
The Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) demonstrated a superior progression-free survival (PFS) benefit compared with combination bendamustine and rituximab across biomarker subgroups of treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome, or del(17p).1
The findings, which come from an analysis of the phase 3 SEQUOIA trial (NCT03336333), were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
In the SEQUOIA trial, fist-line zanubrutinib significantly improved PFS vs bendamustine plus rituximab in patients without del(17p), supporting the use of zanubrutinib in untreated CLL and SLL.2 The new study evaluated PFS in subgroups of patients based on a range of biomarkers, including some known to be negative prognostic factors for CLL.1
Blood samples from patients with CLL and bone marrow samples from patients with SLL collected at screening were assessed for chromosome abnormalities; underwent cytogenetic analysis for complex karyotype (CKT); were analyzed via next-generation sequencing (NGS) for immunoglobulin heavy chain variable (IGHV) gene mutations and expressed clones; and underwent ultrasensitive targeted NGS to analyze mutations across 106 genes.
Better PFS was seen with zanubrutinib vs combination treatment in patients with del(11q) (P < .001), del(13q) (P <.001), trisomy 12 (P < .01), or CKT of at least 3 (P < .01). Median PFS values were not yet reached in the zanubrutinib arm for these subgroups, compared with 29.2 months (P < .001), 40.8 months (P < .001), 40.7 months (P < .01), and 31.1 months (P < .01), respectively, in the combination arm subgroups. Patients without these alterations also showed better outcomes with zanubrutinib vs the combination regimen.
Treatment with zanubrutinib showed similar PFS benefits in patients with del(11q), which is a negative prognostic factor (P = .05), and in those with trisomy 12 (P = .40), which is an intermediate prognostic factor, compared with patients who did not have these these risk factors. The authors also noted that in the zanubrutinib arm, CKT of at least 3 was not associated with worse PFS (P = .18).
Among those with and without IGHV mutations (mIGVH and uIGVH, respectively), PFS was superior in the zanubrutinib arm, and PFS was not affected by IGVH mutation status in the zanubrutinib arm (P = .12). Patients who had uIGVH harboring IGVH1-69 clones—the most prevalent expressed clone in both arms—had significantly better PFS when treated with zanubrutinib vs combination therapy.
Patients with mutations known to confer poor prognosis in CLL, including ATMi, NOTCH1, and SF3B1, showed significantly better PFS in the zanubrutinib arm vs the combination therapy arm, with similar PFS seen between patients with and without these mutations treated with zanubrutinib.
“Importantly, within the [zanubrutinib] treatment arm, patients with negative prognostic biomarkers showed comparable PFS benefit to patients without those markers,” the authors wrote. “Like with other BTK inhibitors, ibrutinib and acalabrutinib, IGHV mutational status did not affect PFS outcome. However, contrary to what has been reported for [treatment-naive] or relapsed/refractory patients treated with ibrutinib-based regimens, CKT of at least 3 was not associated with worse PFS in zanubrutinib-treated patients.”
References
1. Ramakrishnan V, Xu L, Paik JC, et al. Broad superiority of zanubrutinib (Zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p). Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 1902. https://ash.confex.com/ash/2023/webprogram/Paper174543.html
2. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031-1043. doi:10.1016/S1470-2045(22)00293-5
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More